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qDOI of original article: http://dx.doi.org/10.1016/j.yrtph.2014.08.007The Clean Air Act (CAA), among other things, gives the Environ-
mental Protection Agency (EPA) authority and primary responsibil-
ity to assure that the use of automotive fuels and fuel additives
does not present an undue health risk to the general public. If there
are not sufﬁcient data to make such a determination, the CAA also
provides EPA the ability to require that responsible companies gen-
erate the necessary information. The CAA, as amended, requires the
Administrator of EPA to promulgate regulations requiring manu-
facturers of designated fuel and fuel additives (F/FAs) to register
their products with EPA prior to introduction into commerce and
to conduct tests to determine potential health effects of such
products. These regulations can be found at 40 CFR Part 79. They
include regulations that established health effects testing require-
ments for the registration of designated F/FAs as authorized by sec-
tions 211(b) (2) and 211(e) of the CAA (40 CFR, 1994).
The F/FA health effects testing requirements are organized
within a three-tier structure. Tier 1 requires F/FAs manufacturers
to provide EPA (1) the identity and concentration of emissions
products of designated F/FAs, and (2) any available information
regarding the health and welfare effects of certain whole and spe-
ciated emissions (40 CFR 79.52). Tier 2 requires F/FAs manufactur-
ers to test each F/FA for subchronic systemic and organ toxicity, as
well as the assessment of speciﬁc health effects endpoints (40 CFR
79.53). Tier 3 testing may be required, at EPA’s discretion, when
remaining uncertainties as to the signiﬁcance of observed health
or welfare effects, or emissions exposures interfere with EPA’s abil-
ity to reasonably assess the potential risks posed by emissions
from a F/FA (40 CFR 79.54). EPA’s regulations also permit submis-
sion of adequate existing test data in lieu of conducting new tests
that could be duplicative (40 CFR 79.53(b)). In addition, EPA’s reg-
ulations permit health effects testing requirements to be satisﬁed
by participation in groups that are established in accordance with
the grouping criterion set forth at 40 CFR 79.56. The regulations
also include provisions for small businesses and certain types of
products (40 CFR 79.58). For example, manufacturers with total
annual sales that are below certain threshold levels are exempt
from Tier 2 or both Tiers 1 and 2 testing requirements.
At EPA’s discretion, the standard Tier 2 health effects testing
requirements for a designated F/FA (or group thereof) maybe mod-
iﬁed by substituting, adding, or deleting testing requirements; or
changing the underlying vehicle or engine speciﬁcations (40 CFR
79.58(c)). EPA will not, however, delete a testing requirement for a
speciﬁc endpoint in absence of either existing adequate informationor an alternative testing requirement for that endpoint (40 CFR
79.58(c)). When EPA exercises its authority under this provision, it
will allow an appropriate time for completion of the prescribed
alternative tests.
Finally, the introduction into commerce of F/FAs that are not
substantially similar to any F/FA used in vehicle or engine emis-
sions certiﬁcation is prohibited, unless granted a waiver pursuant
to section 211(f)(4) of the Act.
Beginning in 1990, EPA became cognizant of several expert
analyses that demonstrated the necessity for baseline gasoline
and oxygenates health effects testing. They included a committee
of the National Science and Technology Council that reviewed pub-
lished and unpublished reports made available since 1990). This
committee identiﬁed the following areas in an Interagency Assess-
ment as requiring additional research: human exposures, pharma-
cokinetics of MTBE; acute health effects related to oxygenates,
mechanisms of carcinogenicity; and dose–response relationships
between exposure to oxygenates and risk of carcinogenicity
(NSTCC, 1997). Similarly, the Health Effects Institute for Oxygen-
ates Evaluation Committee conducted an intensive review of the
existing oxygenates health effects database, EPA risk assessments,
and health effects of new oxygenates as they relate to other pollu-
tants whose emissions are altered by use of oxygenates. The Oxy-
genate Evaluation Committee identiﬁed the following outstanding
research needs: personal exposures to oxygenates using standard
protocols, metabolism of MTBE; pharmacokinetics of other ethers;
short-term effects using controlled human exposures; neurotoxic
effects, neoplastic and non-neoplastic long-term effects; studies
on the genotoxicity of MTBE; developmental effects, and assess-
ment of potential contamination of drinking water with MTBE
(Health Effects Institute, 1996). Additionally, a Committee of the
National Research Council reviewed the Interagency Assessment
and identiﬁed the following research needs: representative per-
sonal exposure monitoring of MTBE in the exposed population;
toxicokinetic data of MTBE and other oxygenates; study of expo-
sure to MTBE and acute health effects; and potential for biodegra-
dation of MTBE and other alkyl ether oxygenates in surface water,
soil and groundwater (National Research Council, 1996). The
expert analyses clearly demonstrated this necessity for testing
focusing on acute health effects, exposure assessments, pharmaco-
kinetic parameters, and potential exposures via drinking water.
EPA concluded in a review of the Interagency Assessment and
the Health Effects Institute Review: ‘‘It is quite evident, however,
that a consistent theme in all the reports is a need for more infor-
mation on the exposure and health aspects of conventional and
oxygenated fuels’’ (EPA, 1996).
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tute (API) test group consortium (hereinafter the Section 211(b)
Research Group) of proposed Alternative Tier 2 health effects
testing requirements for baseline gasoline and baseline gasoline
containing methyl tertiary butyl ether (MTBE) and oxygenated
non-baseline gasolines, and the proposed schedule for completion
and submission of such tests. The consortium comprised manufac-
turers of gasoline with or without the fuel additive MTBE, ethyl ter-
tiary butyl ether (ETBE), ethyl alcohol (EtOH), tertiary amyl methyl
ether (TAME), diisopropyl ether (DIPE), and tertiary butyl alcohol
(TBA) and manufacturers of these oxygenates and other gasoline
additives. An associated Federal Register notice (62 FR 474000) ini-
tiated a 60-day public comment period, which was extended an
additional 60 days (62 FR 60675), to accommodate both the Sec-
tion 211(b) Research Group’s request for an extension, and to also
allow the general public additional time to provide comments. On
November 2, 1998, EPA notiﬁed the Section API 211(b) Research
Group of the speciﬁc tests required under the Alternative Tier 2
provisions, under the F/FA health effects testing requirements of
40 CFR 79 (Subpart F), for baseline gasoline and oxygenated non-
baseline gasolines, and the schedule for completion and submis-
sion of such tests. A copy of the ﬁnal notiﬁcation letter as well as
the tests and schedule under the Alternative Tier 2 provisions were
placed in the Public Docket Number A-96–16 (EPA, 1998). On
December 9, 1998, the Agency published a notice announcing that
EPA had notiﬁed the Section 211(b) Research Group of the ﬁnal
Alternative Tier 2 health effects testing requirements under 40
CFR 79.58(c) (63 FR 67877).
In accordance with 40 CFR 79.56(a), manufacturers of F/FAs
were permitted to satisfy the Alternative Tier 2 testing require-
ments on a group basis. Group representatives were formed in
accordance with 40 CFR 79.56(e)(4)(i)(A). Each individual manu-
facturer that was a member of such a group, however, was individ-
ually subject to the testing and data submission requirements
unless otherwise exempt under certain provisions of 40 CFR 79.
The baseline gasoline group was represented by the Gasoline Base
Fuel speciﬁed in 40 CFR 79.55(b). Each oxygenate-gasoline group
was represented by a formulation comprised of the oxygenate in
question (chemical grade or better) mixed in the Gasoline Base
Fuel (as speciﬁed in Section 79.55(b)) to achieve the following vol-
ume percent: Methyl Tertiary Butyl Ether (15 volume percent),
Ethyl alcohol (10 volume percent), Ethyl Tertiary Butyl Ether (17
volume percent), Tertiary amyl methyl ether (17 volume percent),
Di-isopropyl ether (17 volume percent), and Tertiary butyl alcohol
(12 volume percent). For the purposes of conducting inhalation
exposure studies, the provisions of 40 CFR 79.53(c)(1) applied.
The F/FA program guidelines for Good Laboratory Practices (GLP),
as provided at 40 CFR 79.60 were in effect for purposes of the
entire testing regimen. The provisions of 40 CFR 79.61 were used
for purposes of conducting the inhalation exposure studies.
Detailed, written, and where applicable, peer-reviewed protocols
were developed by the 211(b) Research Group and approved by
EPA prior to the initiation of any of the required Alternative Tier
2 inhalation exposure studies. Where applicable, the objectives
and methods for performing assessments were conducted in accor-
dance with relevant provisions of the Health Effects Test Guide-
lines (Pt. 870) published by the Ofﬁce of Prevention, Pesticides
and Toxic Substances (OPPTS) (Docket Item A-96–16/II-1). For fur-
ther information on the speciﬁc requirements and objective of this
test program, please refer to the ﬁnal notiﬁcation letter5 and the
public record (Federal Docket, 2003).
The Alternative Tier 2 testing regimen contrasts with the stan-
dard Tier 2 requirements, which may require testing of both evap-
orative and combustion emissions because toxicological studies
were based on animal exposures to only evaporative emissions
mixtures of baseline gasoline or an oxygenated fuel that is blendedinto the baseline gasoline in question. The decision to focus on
evaporative emissions exposure studies only was based in part
on peer-reviewed arguments presented by the Section 211(b)
Research Group. As a result of an API-sponsored information meet-
ing on December 11 and 12, 1995, toxicological experts presented
analysis demonstrating that relatively high concentrations of car-
bon monoxide (CO) in gasoline exhaust imposed a practical limit
on achievable exposures to hydrocarbon (HC) exhaust compo-
nents. General agreement was reached among peer-reviewed
experts in the ﬁeld of toxicological testing that the amount of
exhaust gas dilution required to avoid CO toxicity of animal
subjects would bring the concentration of HCs in the exposure
chamber below the no-effect level. At that time, it was concluded
that further exhaust emission toxicological tests of gasoline-based
F/FAs would not produce meaningful results. At that time also, EPA
scientists generally concurred that further inhalation toxicological
testing of gasoline-based combustion emissions, if conducted using
the approach described in the F/FA rule, seemed unlikely to provide
additional useful data for a comparative risk assessment. Their
concurrence was based on the likelihood that, at the exhaust dilu-
tion ratios necessary to avoid acute CO toxicity, the effects of the
inhaled combustion mixture would be dominated by exposure to
CO and/or oxides of nitrogen (NOx) rather than by HCs of primary
interest. This concurrence did not, however, provide a resolution of
either cancer or non-cancer health risks of gasoline (or oxygenated
fuel) combustion emissions. On the contrary, the reviewing EPA
scientists recommended continued evaluation of other approaches
for investigating gasoline exhaust toxicity, such as the use of syn-
thesized surrogate exhaust mixtures, the use of different exposure
routes, and/or development of analytical models to assess compar-
ative risks.
In sum, the general objectives of this test program were
threefold. (1) Develop a comprehensive characterization of the
toxicological effects in test animals of inhalation exposures to
evaporative emissions of Baseline Gasoline and (separately)
MTBE-gasoline; (2) determine potential dose–response relation-
ships and No Observed Adverse Effects Levels (NOAELs) for speciﬁc
toxicological endpoints; and (3) together with information from
related studies on human population exposure levels, this informa-
tion should permit accurate quantitative comparisons of the rela-
tive toxicological risks of baseline gasoline and MTBE-oxygenated
fuels blended into baseline gasoline, as well as providing a solid
basis for comparison with other oxygenate-gasoline fuel formula-
tions. The required assessments included basic inhalation toxicity
in the context of a subchronic exposure, as well as tests to deter-
mine potential reproductive, developmental, neurotoxic, immuno-
toxic, mutagenic, and carcinogenic (chronic exposure) effects.
Thus, the Alternative Tier 2 testing programwas not intended to
address every identiﬁed research need on baseline gasoline and the
various oxygenated fuels blended into baseline gasoline. Rather,
the test program was intended to ﬁll critical gaps and act as a
screen to determine the need for additional information that may
be necessary to enable the Agency to make decisions concerning
the potential risks associated with these F/FAs. EPA believed, how-
ever, at the time of requiring this testing program that the public
interest would be best served by timely initiation of appropriate
toxicity testing on the evaporative emissions of baseline gasoline
and certain oxygenated fuels blended into baseline gasoline while
the Agency continued to evaluate the complex issues surrounding
exhaust emissions testing. EPA received no public comments dis-
agreeing with this approach. EPA also recognized that the results
of evaporative emissions tests, together with information on
human population exposures to various evaporative and combus-
tion emissions components, may change current perceptions about
the continued need for, and speciﬁc targets of, future combustion
emissions studies. Potential requirements to investigate the
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3 level.
Consistent with the general strategy of the F/FA testing program,
the Alternative Tier 2 testing regimenwas part of a tiered approach,
whichmay also include future Tier 3 test requirements. Such a step-
wise approach helps to ensure a wise investment of manufacturer
and laboratory resources. It also allows the Alternative Tier 2 results
to inﬂuence the objectives and design of any necessary follow-up
studies at the Tier 3 level. Changes in the F/FA usage pattern over
time may also alter future research priorities. Furthermore, some
information gaps may be ﬁlled by other studies currently being
conducted; conversely, research work that EPA understands to be
either ongoing or planned may not be done after all, may be inade-
quately performed, or may raise important new concerns that must
be evaluated. Thus, the Alternative Tier 2 requirements must be
regarded as the ﬁrst step in a test regimen, which may encompass
one or more additional steps at the Tier 3 level.
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